- Home
- CRNX vs NAMS Comparison
CRNX vs NAMS Comparison
Compare CRNX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- NAMS
- Stock Information
- Founded
- CRNX 2008
- NAMS 2019
- Country
- CRNX United States
- NAMS Netherlands
- Employees
- CRNX N/A
- NAMS N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- NAMS Health Care
- Exchange
- CRNX Nasdaq
- NAMS Nasdaq
- Market Cap
- CRNX 2.8B
- NAMS 3.1B
- IPO Year
- CRNX 2018
- NAMS N/A
- Fundamental
- Price
- CRNX $41.56
- NAMS $36.24
- Analyst Decision
- CRNX Buy
- NAMS Strong Buy
- Analyst Count
- CRNX 12
- NAMS 9
- Target Price
- CRNX $74.45
- NAMS $42.78
- AVG Volume (30 Days)
- CRNX 2.1M
- NAMS 1.3M
- Earning Date
- CRNX 11-06-2025
- NAMS 11-05-2025
- Dividend Yield
- CRNX N/A
- NAMS N/A
- EPS Growth
- CRNX N/A
- NAMS N/A
- EPS
- CRNX N/A
- NAMS N/A
- Revenue
- CRNX $1,392,000.00
- NAMS $64,006,000.00
- Revenue This Year
- CRNX $428.87
- NAMS N/A
- Revenue Next Year
- CRNX $958.11
- NAMS $1.67
- P/E Ratio
- CRNX N/A
- NAMS N/A
- Revenue Growth
- CRNX 0.51
- NAMS 762.15
- 52 Week Low
- CRNX $24.10
- NAMS $14.06
- 52 Week High
- CRNX $62.53
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- CRNX 54.07
- NAMS 63.80
- Support Level
- CRNX $43.72
- NAMS $36.16
- Resistance Level
- CRNX $45.95
- NAMS $41.47
- Average True Range (ATR)
- CRNX 1.78
- NAMS 2.46
- MACD
- CRNX -0.37
- NAMS 0.47
- Stochastic Oscillator
- CRNX 19.30
- NAMS 60.61
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.